Free Trial

Context Therapeutics (CNTX) News Today

Context Therapeutics logo
$1.00 +0.06 (+5.97%)
As of 04:00 PM Eastern
Context Therapeutics Inc. stock logo
Context Therapeutics (NASDAQ:CNTX) Now Covered by William Blair
William Blair started coverage on Context Therapeutics in a report on Monday. They set an "outperform" rating on the stock.
Context Therapeutics Inc. stock logo
Context Therapeutics Inc. (NASDAQ:CNTX) Given Consensus Rating of "Buy" by Analysts
Context Therapeutics Inc. (NASDAQ:CNTX - Get Free Report) has been assigned a consensus recommendation of "Buy" from the seven brokerages that are currently covering the stock, Marketbeat reports. Six research analysts have rated the stock with a buy rating and one has assigned a strong buy ratin
Context Therapeutics Inc. stock logo
Context Therapeutics Inc. (NASDAQ:CNTX) Stock Holdings Trimmed by Affinity Asset Advisors LLC
Affinity Asset Advisors LLC lessened its position in shares of Context Therapeutics Inc. (NASDAQ:CNTX - Free Report) by 23.1% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,015,340 shares of the compa
Context Therapeutics Inc. stock logo
Franklin Resources Inc. Purchases 2,149,392 Shares of Context Therapeutics Inc. (NASDAQ:CNTX)
Franklin Resources Inc. lifted its position in Context Therapeutics Inc. (NASDAQ:CNTX - Free Report) by 115.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,003,380 shares of the compa
Context Therapeutics Inc. stock logo
Context Therapeutics (NASDAQ:CNTX) Receives "Buy" Rating from D. Boral Capital
D. Boral Capital reiterated a "buy" rating and issued a $9.00 target price on shares of Context Therapeutics in a report on Wednesday.
Context Therapeutics doses first patient in Phase 1 trial of CT-95
Context Swoons on CT-95 First Dose
Context Therapeutics Inc. stock logo
Context Therapeutics Inc. (NASDAQ:CNTX) Receives Consensus Rating of "Buy" from Analysts
Context Therapeutics Inc. (NASDAQ:CNTX - Get Free Report) has earned an average rating of "Buy" from the seven brokerages that are presently covering the company, Marketbeat Ratings reports. Six research analysts have rated the stock with a buy recommendation and one has assigned a strong buy rec
Context Therapeutics Inc. stock logo
What is HC Wainwright's Forecast for CNTX Q3 Earnings?
Context Therapeutics Inc. (NASDAQ:CNTX - Free Report) - Equities research analysts at HC Wainwright issued their Q3 2025 earnings estimates for shares of Context Therapeutics in a research report issued on Friday, March 21st. HC Wainwright analyst E. Bodnar anticipates that the company will post
Context Therapeutics Inc. stock logo
Context Therapeutics (NASDAQ:CNTX) Issues Quarterly Earnings Results
Context Therapeutics (NASDAQ:CNTX - Get Free Report) posted its quarterly earnings results on Thursday. The company reported ($0.04) EPS for the quarter, topping analysts' consensus estimates of ($0.05) by $0.01.
Context Therapeutics Inc. stock logo
Context Therapeutics (NASDAQ:CNTX) Earns "Buy" Rating from D. Boral Capital
D. Boral Capital reiterated a "buy" rating and issued a $9.00 target price on shares of Context Therapeutics in a research report on Friday.
Context Therapeutics Inc. stock logo
Context Therapeutics (NASDAQ:CNTX) Receives "Buy" Rating from HC Wainwright
HC Wainwright restated a "buy" rating and issued a $5.00 price target on shares of Context Therapeutics in a report on Friday.
Context Therapeutics Inc. stock logo
Context Therapeutics (CNTX) to Release Earnings on Thursday
Context Therapeutics (NASDAQ:CNTX) will be releasing earnings before the market opens on Thursday, March 20, Financial Modeling Prep reports.
Context Therapeutics Inc. stock logo
Context Therapeutics Inc. (NASDAQ:CNTX) Receives Average Recommendation of "Buy" from Brokerages
Shares of Context Therapeutics Inc. (NASDAQ:CNTX - Get Free Report) have earned an average recommendation of "Buy" from the seven ratings firms that are presently covering the firm, Marketbeat Ratings reports. Six research analysts have rated the stock with a buy recommendation and one has given a
Context Therapeutics Inc. stock logo
Context Therapeutics (NASDAQ:CNTX) Shares Up 2.1% - Time to Buy?
Context Therapeutics (NASDAQ:CNTX) Shares Up 2.1% - Should You Buy?
Context Therapeutics Inc. stock logo
Context Therapeutics Inc. (NASDAQ:CNTX) Given Average Rating of "Buy" by Brokerages
Shares of Context Therapeutics Inc. (NASDAQ:CNTX - Get Free Report) have received a consensus recommendation of "Buy" from the seven brokerages that are currently covering the stock, Marketbeat Ratings reports. Six investment analysts have rated the stock with a buy rating and one has issued a st
Context Therapeutics Inc. stock logo
Context Therapeutics Inc. (NASDAQ:CNTX) Short Interest Update
Context Therapeutics Inc. (NASDAQ:CNTX - Get Free Report) was the recipient of a significant increase in short interest in December. As of December 31st, there was short interest totalling 1,530,000 shares, an increase of 55.1% from the December 15th total of 986,300 shares. Based on an average daily volume of 501,500 shares, the short-interest ratio is presently 3.1 days. Currently, 2.6% of the shares of the stock are sold short.
Context Therapeutics Inc. stock logo
D. Boral Capital Reaffirms Buy Rating for Context Therapeutics (NASDAQ:CNTX)
D. Boral Capital restated a "buy" rating and issued a $9.00 price objective on shares of Context Therapeutics in a research report on Wednesday.
Context doses first patient in Phase 1 clinical trial evaluating CTIM-76
Context Therapeutics Appoints Andy Pasternak As Board Chairman
Context Therapeutics Inc. stock logo
Context Therapeutics (NASDAQ:CNTX) Upgraded to Strong-Buy at Citizens Jmp
Citizens Jmp upgraded Context Therapeutics to a "strong-buy" rating in a report on Wednesday.
Get Context Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CNTX and its competitors with MarketBeat's FREE daily newsletter.

CNTX Media Mentions By Week

CNTX Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

CNTX
News Sentiment

0.81

0.72

Average
Medical
News Sentiment

CNTX News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

CNTX Articles
This Week

8

2

CNTX Articles
Average Week

Get Context Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CNTX and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:CNTX) was last updated on 4/24/2025 by MarketBeat.com Staff
From Our Partners